This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Reuven Agami group


Reuven Agami

Group leader, Head of Division

Personal details


Reuven Agami performed his PhD research (Thesis: Cell cycle and apoptosis control induced by the tyrosine kinase c-Abl) within the department of molecular genetics at the Weizmann Institute of Science, Israel. During his research he identified a novel DNA-damage-induced apoptosis pathway. As a post-doc in the group of Rene Bernards he investigated rapid molecular events that initiate a p53 independent DNA damage response. In September 2001 he started his own group at the Netherlands Cancer Institute, which consists now of a senior postdoc, six postdocs, three PhD students and two technician. His group developed first an RNAi vector system (pSUPER) to stably knockdown genes in mammalian cells, and then used it to identify novel human tumor suppressor genes. Subsequently, his group developed a microRNA expression vector and library and used it to identify oncogenic miRNAs.

Currently, the Agami team is studying the role of non-protein coding RNAs and protein translation in cancer metastasis, cellular response to cancer therapy, and acquired resistance. The team characterizes novel RNA functions, and tests their impact on cancer progression. Their goal is to drive lab discoveries to the benefit of cancer diagnosis and therapy.

Share this page